Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere
Boehringer Ingelheim will pair up with Simcere Pharmaceutical in one of the hottest targets in immunology.
For €42 million ($50 million) upfront, the German pharma will tap into Simcere's preclinical TL1AxIL-23p19 bispecific antibody for inflammatory ...
⚠️ 风险分析 中
摘要：中德药企合作涉及技术出口与知识产权跨境转移，需关注合规风险。
影响：合作涉及生物技术转让，可能触发出口管制审查，影响交易进度与知识产权保护。
建议：评估技术出口许可要求，完善知识产权协议，确保跨境合作符合中美欧相关法规。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.